acquired
Stage
2
Investors
About
Algeta ASA develops, manufactures, and markets targeted radiopharmaceutical therapies for cancer treatment, including its lead compound Alpharadin, designed for treating bone metastases.
Explore Algeta ASA's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.